For the Inventor, By the Inventor

Enter assignee name

Luxembourg, Luxembourg

Euro-Celtique S.a.

Calculating rank

USPTO Granted Patents = 270

% Expired Patents = 13.3

CIPO Patents = 46

EPO Patents = 122

Forward Citations = 22,830

Loading Chart...

Loading Chart...

224 inventors (with patents filed for the assignee):

Mark Chasin (66 out of 80 patents)

Stewart Thomas Leslie (40 out of 41 patents)

Benjamin Oshlack (39 out of 157 patents)

4. Ronald Brown Miller (32 out of 32 patents)

5. Peter Hofer (29 out of 34 patents)

6. David J Cavalla (29 out of 44 patents)

7. Derek Allan Prater (28 out of 37 patents)

8. Sandra Therese Malkowska (26 out of 26 patents)

9. Paul D Goldenheim (20 out of 37 patents)

10. Richard S Sackler (20 out of 48 patents)

11. Donald Kyle (19 out of 341 patents)

12. Hassan Mohammad (15 out of 17 patents)

13. Robert F Kaiko (12 out of 30 patents)

14. Malcolm Walden (11 out of 17 patents)

15. Nancy C Lan (11 out of 26 patents)

Core Competencies:

Dihydroetorphine

Hydromorphone

Oxycodone

Tamper Resistant Formulations

Pain Relief

Drug Delivery Systems

Sustained Release

Therapeutic Agents

Pharmaceutical Compositions

Gastroretentive Systems

Analgesics

Controlled Release

270 patents: Sort by Forward Citations

1. 10898479 - Dihydroetorphine for the provision of pain relief and anaesthesia (2021-01-26),

2. 10745406 - Dihydroetorphines and their preparation (2020-08-18),

3. 10688258 - Dispenser cap arrangement (2020-06-23),

4. RE47884 - Dispenser (2020-03-02),

5. 10258616 - Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome (2019-04-16),

6. 10231936 - Delayed release pharmaceutical formulations (2019-03-19),

7. 10071089 - Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation (2018-09-11),

8. 9993433 - Manufacturing of active-free granules and tablets comprising the same (2018-06-12),

9. 9987441 - Counter (2018-06-05),

10. 9901540 - Combination of active loaded granules with additional actives (2018-02-27),

11. 9814710 - Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome (2017-11-14),

12. 9814679 - Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug (2017-11-14),

13. 9805300 - Counter (2017-10-31),

14. 9782359 - Opioid composition for treating skin lesions (2017-10-10),

15. 9764102 - Dispenser cap arrangement (2017-09-19),

Company Overview

Euro-Celtique S.a., headquartered in Luxembourg, specializes in the development and manufacturing of pharmaceutical formulations with a focus on pain relief. The company is recognized for its expertise in tamper-resistant formulations and advanced drug delivery systems, particularly involving therapeutic agents such as dihydroetorphine, hydromorphone, and oxycodone. Euro-Celtique is committed to enhancing patient safety and efficacy through sustained release technologies, positioning itself as a key player in the pharmaceutical industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

270 Patents

#4 in Luxembourg

#4 in Luxembourg

#3,259 in the World

Luxembourg, Luxembourg

Euro-Celtique S.a.

Forward Citations = 22,830

224 inventors:

Mark Chasin (66 out of 80 patents)

Stewart Thomas Leslie (40 out of 41 patents)

Benjamin Oshlack (39 out of 157 patents)

4. Ronald Brown Miller (32 out of 32 patents)

5. Peter Hofer (29 out of 34 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Euro-Celtique S.a.. Retrieved from https://idiyas.com/company/euro-celtique-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…